In an embodiment, the niacin analog has an EC50 for β arrestin mediated GPR109A function which is at least 10 times greater than {HEAD ~ the EC50} of niacin for {TAIL ~ β arrestin} mediated GPR109A function 
In an embodiment , the niacin analog has an EC50 for β arrestin mediated GPR109A function which is at least 10 times greater than { HEAD ~ the EC50 } of niacin for { TAIL ~ β arrestin } mediated GPR109A function
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH